Could a single cell infusion replace lifelong Anti-Rejection drugs?
NCT ID NCT03726307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a single infusion of special immune cells (regulatory dendritic cells) from the kidney donor can help the recipient's body accept the new kidney with fewer side effects. 14 first-time kidney transplant recipients will receive the cells one week before surgery and be followed for two years. The main goal is to check safety, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pittsburgh, Starzl Transplantation Institute
Pittsburgh, Pennsylvania, 15213, United States